MODERN TREATMENT AND CORRECTION OF THE CONSEQUENCES OF LOCALIZED SCLERODERMA

Abstract

Localized scleroderma (LS) is an inflammatory sclerosing disease of the skin and subcutaneous tissues associated with their atrophy. Depending on the subtype, severity of the disease and localization of the lesion, involvement in the pathological process of adipose tissue, muscles, joints and bones, but not internal organs, is noted. The annual primary incidence of drugs in childhood is 3.4 cases per 1,000,000 child population; in females, the disease occurs 2.6–6 times more often. The wide range of clinical manifestations of the disease has led to the emergence of a large number of different classifications, which take into account the severity, prevalence and depth of the fibrosis process, as a result of which five main clinical forms of LS are distinguished: limited, generalized, linear, deep and mixed. The forms of drugs are not mutually exclusive, since the same patient may experience different manifestations of the disease. One of the most common forms of LS in childhood is the linear form, which is observed in approximately 40–70% of children.